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To identify cytokines that can activate and expand NK cells in the presence of prostate cancer 
cells in order to determine whether these agents may be useful in future intratumoral 
administration in pre-clinical and clinical prostate cancer trials.  
Materials and Methods 
Lymphocytes isolated from normal donor blood were set up in co-cultures with either cancer 
or non-cancerous prostate cell lines, together with each of the cytokines IL-2, IL-12, IL-15, 
Interferon gamma (IFN-γ) or IL-21 for a period of 7 days. Then, expansion of NK cells, NKT 
cells and CD8 T cells was measured by flow cytometry and compared with the expansion of 
the same cells in the absence of prostate cells. The cytotoxic activity of NK cells as measured 
by perforin and tumour cell killing was also assessed. NK cell receptors and their 
corresponding ligands on prostate tumour cells were analysed to determine whether any of 
these were modulated by co-culture. The role of the tumour secreted heat shock proteins 
HSP90 and HSP70 in expansion of NK cells in the co-cultures was also investigated due to 
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Results 
We show that only IL-15, among a panel of cytokines known to cause NK cell activation and 
expansion, can actively induce expansion of NK, NKT and CD8 T cells in the presence of 
prostate cancer cell lines. Furthermore, the expansion of NK cells is far greater (up to 50% 
greater) in the presence of the cancer cells (LNCaP, PC3) than when lymphocytes are 
incubated alone. In contrast, non-cancerous cell lines (PNT2 and WPMY-1) do not exert any 
expansion of NK cells. The cytolytic activity of the NK cells, as measured by perforin, 
CD107a and killing of tumour cells is also greatest in co-cultures with IL-15. Examination of 
NK cell receptors shows that NKG2D is upregulated to a greater degree in the presence of 
prostate cancer cells, compared with the upregulation with IL-15 in lymphocytes alone. 
However, blocking of NKG2D does not inhibit the enhanced expansion of NK cells in the 
presence of tumour cells.  
Conclusions 
IL-15 is the only cytokine among a panel of NK cell activating cytokines that can stimulate 
expansion of NK cells in the presence of prostate cancer cells. Therefore IL-15 may be a 
good candidate for novel future intratumoral therapy of the disease. 
  
Introduction 
Immunosuppression exerted by the tumour microenvironment is a major challenge in tumour 
immunotherapy.  In particular, the prostate cancer microenvironment exerts considerable 
immunosuppressive effects as shown by the presence of anergic NK and T cells, and 
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tumour type [1, 2]. However, the finding that lymphocytes infiltrate the cancerous prostate, 
combined with the knowledge of prostatic antigens such as  prostate-specific acid 
phosphatase (PAP), prostate-specific membrane antigen (PSMA), and NKX3.1 present on 
cancer cells in higher amounts than on normal cells, [3-5], led to the advent of prostate cancer 
vaccines, such as Provenge™ [6], that created new interest in the use of immunotherapies 
against prostate cancer. However, in prostate cancer, no significant clinical responses have 
been observed with well-known checkpoint immunotherapies such as Ipilimumab, anti-PDL1 
or anti-PD-1[7, 8], although a minority of patients (5%)  treated with the latter agents are 
responsive due to defects in genomic instability or DNA mismatch repair genes causing 
increases in tumour mutational burden and neoantigen expression[9-11]. The regulation of 
expression of these checkpoint proteins is also still not understood. As novel checkpoints 
either on tumour cells or the surrounding cells of the milieu are being discovered regularly, it 
may be impossible to target all of these as a therapeutic approach to block 
immunosuppression in the tumour lesion.   
Therefore, agents that can drive the activation and proliferation of NK and other effector cell 
populations within the cancer microenvironment may give a more favorable response than 
multiple antibodies directed at single immunomodulatory checkpoint targets.   
One of the most promising cytokines in cancer immunotherapy is Interleukin 15 (IL-15). IL-
15 is a pleiotropic cytokine with two receptors common to IL-2 (IL2Rβ (CD122) and IL2Rγ 
(CD132)) in addition to its individual receptor, the IL-15 alpha receptor (IL-15Rα (CD215) 
[12]. These receptors can be found on haematopoietic cell types including NK cells, 
monocytes, and T cells. IL-15 is secreted from cell types including dendritic cells, monocytes 
and epithelial cells and activates both NK and CD8 T cells among a number of immune 
effector cells; therefore it has been identified as an agent that can induce anti-tumour 
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proliferate in the presence of IL-15 both in-vitro and when adoptively transferred into 
animals[14]. IL-15 has been shown to effectively reduce prostate tumour volume in TRAMP-
C2 challenged C57-BL6 mice[15]. In addition, a number of studies involving in-vivo murine 
tumour challenge models using IL-15 transfected tumour cell lines, including prostate cancer 
cell lines, have shown that these tumours exhibit greatly reduced growth and a marked 
infiltration of NK cells and macrophages[16-18]. This is due to the fact that IL-15 can 
upregulate the expression of the receptors CXCL9 and CXCL10 on epithelial cells, which 
leads to recruitment of NK cells to these cells through CXCR3[19]. Moreover, heat shock 
proteins such as HSP70, that are secreted constitutively by many tumour cell lines, but not by 
normal epithelial cells have been reported to increase IL-15 or IL-2 mediated expansion of 
immune cells including NK cells [20-23]. 
However, IL-15 and other therapeutic cytokines used in anti-cancer therapy such as IL-2, IL-
12 and IL-21 have not been studied in the context of their effects on immune effector cells 
exposed to prostate cancer cells.  We therefore examined the effects of IL-15 and several 
other TH1 promoting therapeutic cytokines on NK and CD8 T cell expansion and cytotoxic 
function in the absence or presence of a number of prostate cancer and non-cancerous 
prostate cell lines using an in-vitro co-culture model.  The effects of IL-15 on the expression 
of a number of NK cell receptors and their ligands were also examined in the co-cultures. In 
addition, we also assessed whether IL-15 in co-cultures of lymphocytes and cancer cells was 
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Materials and Methods: 
Cell lines 
The cell lines LNCaP, PC-3, PNT2, WPMY-1 and TRAMP-C1 were obtained in the last 3 
years from the ATCC (LGC standards, UK).  LNCaP and PC3 are human metastatic prostate 
epithelial carcinomas. TRAMP-C1 is a tumourigenic mouse prostate adenocarcinoma cell 
line obtained from the transgenic adenocarcinoma of the mouse prostate (TRAMP) 
immunocompetent C57/BL6 mouse prostate model. PNT2 is an epithelial prostate cell line 
derived from normal prostate epithelial cells that has been immortalized with SV40. WPMY-
1 is a myofibroblast stromal cell line also immortalized by SV40.  WPMI and PNT2 are 
termed “non-cancerous cells” in this investigation. 
LNCaP, PC-3, and PNT2 cell lines were cultured in RPMI medium containing, 2mM 
glutamine, 100 units/ml of penicillin and streptomycin (Sigma Aldrich UK) and 10% foetal 
bovine serum (Life Technologies UK) (RPMI complete medium). WPMY-1 cells were 
cultured in DMEM medium supplemented as above. TRAMP-C1 cells were cultured in 
DMEM with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L 
glucose, supplemented with 0.005 mg/ml bovine insulin and 10 nM dehydroisoandrosterone, 
5% Nu-Serum IV (all components from Sigma Aldrich, UK), and 5% fetal bovine serum.  
 
Isolation of PBMCs, and depletion of CD8 T cells or CD56+ cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors using 
anonymized leukodepletion cones (Blood Transfusion Service, NHS Blood and 
Transplantation). Blood from the leukodepletion cones was diluted by 50% in Hanks buffered 
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Aldrich UK) using 50 ml Falcon tubes. The PBMCs were then prepared from the buffy coats 
as previously described [24].To prepare non–adherent PBMCs for the co-cultures of 
lymphocytes and prostate cancer cells, PBMCs were added to 175cm
2
 culture flasks at 3 x10
6
 
cells/ml in RPMI complete medium and left for 3 h to adhere to the plastic. After 3 h, the 
non-adherent cells were harvested for use in the co-cultures. 
PBMCs were depleted of CD8 T cells or CD56+ cells using a Miltenyi isolation kit as per 
manufacturer’s instructions. Depletions were successful with a removal of at least 99% of the 
CD56+ or CD8+ populations from these lymphocytes. 
Lymphocyte: Cancer cell Co-Culture  assay 
Non-adherent PBMCs were co-cultured with cancer or non-cancerous prostate cell lines for 7 
days at a ratio of 8:1 in 24-well plates using a working concentration of 8 x 10
5
 PBMCs to 1 x 
10
5
 prostate cells. The 8:1 ratio had been previously shown to give the optimal NK expansion 
and NK cell cytotoxic activity following co-cultures carried out at 1:1, 2:1, 4:1, and 20:1 of 
lymphocytes to prostate cells[25]. To these cultures, cytokines were added, either IL-2, IL-
12, IL-15, INF-γ, or IL-12 at a dose of 25 ng/ml (all cytokines from Peprotech, UK). The 25 
ng/ml dose was used as this gives maximal secretion of IFN-γ from NK cells (ED50s of the 
cytokines range from 0.1-2 ng/ml according to the Peprotech datasheets). Prostate cells were 
irradiated with 4 grays using a gamma irradiator to inhibit their proliferation during the 7 day 
co-culture with minimal effects on their viability [26]. In some experiments, a 0.4µM 
transwell filter was included, (referred to as an insert), between the lymphocytes and the 
prostate cells, to determine whether proliferation of effector cells occurred in the absence of 
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For co-cultures using murine cells, splenocytes were isolated from the spleens of C57BL6 
mice (aged 10-12 weeks), treated with red cell lysis buffer to remove red blood cells and then 
MHC class II depleted (kit from Miltenyi UK) to remove monocytes and macrophages. The 
resulting lymphocytes were co-cultured at an 8:1 ratio using the murine forms of the above 
cytokines at 25 ng/ml each using a working concentration of 8 x 10
5
 splenocytes to 1 x 10
5
 
irradiated TRAMP-C1 tumour cells for 9 days.  
For all cultures, medium, and cytokines in the wells was replenished at day 3 to prevent 
nutrient loss to the cells. Lymphocyte viability in the presence of the cytokines was always 
>90%. 
 
Analysis of NK, NKT and T cell expansion, cytotoxic activity, and killing of tumour cells 
NK, NKT , T cells and regulatory T cells (Tregs) populations within the PBMCs were 
measured using a BD FACsCalibur™ (BD Biosciences UK) with fluorophore conjugated 
mouse anti-human anti-CD4 (clone A161A1), CTLA-4 (clone BNI3), CD25 (clone BC96) 
and FOXP3 (clone 206D) (Biolegend, UK) for the Treg analysis and anti-human CD56 
(clone MEM-188), CD3 (clone HIT1A) (Biolegend UK) and CD8 (clone BW135/80) 
(Miltenyi Biotech, UK) for the  NK, NKT and CD8 T cells. Standard protocols for surface 
flow cytometric staining were followed to detect surface markers 
(https://www.biolegend.com/protocols/cell-surface-flow-cytometry-staining-protocol/4283/), 
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The immune cell mediated killing of the human tumour cells was measured using annexin/ 
propidium iodide (PI) staining after the 7-day co-culture, followed by flow cytometric 
analysis.  
Murine NK, NKT cells, CD8 T cells and Tregs was measured using flow cytometry with a 
BD FACsCalibur and the antibodies used (Biolegend UK) were anti-mouse NK1.1 (clone 
PK136), CD3 (clone 17A2), and CD8 (clone 53-6.7). Killing of TRAMP-C1 cells was 
measured by culturing the primed MHC class II depleted splenocytes, (or NK cells or CD8 T 
cells purified from the MHC class II depleted splenocytes by Miltenyi  isolation kits) from 
the 9 day assay with fresh TRAMP-C1 cells and observing killing after 24 hrs with a 
live/dead assay (Thermofisher UK). The cytotoxic activity of the NK, NKT and CD8 T cells 
in the human co-cultures was assessed using antibodies to perforin (clone dG9), and CD107a 
(clone H4A3) (Biolegend UK). In these experiments, cells were either fixed and 
permeabilised prior to antibody staining as described in the Biolegend intracellular protocol 
(for perforin) or cells were treated with Brefeldin A for 4 hrs prior to addition of CD107a 
antibody to stop release of CD107a from the cell surface, and then staining with the cell 
surface marker protocol.  
 
Measurement of the expression of NK receptors on NK cells and NK ligands on tumour cells 
To investigate the mechanisms of the IL-15 mediated expansion of NK cells in the presence 
of prostate tumour cells, a panel of antibodies to inhibitory and activatory NK cell receptors 
was used to stain NK cells in the co-cultures that were prepared as shown above. The 
antibodies used were mouse anti human FITC-conjugated anti-NKG2D (1D11), anti-DNAM-
1 (Clone 11A8), anti-NKP30 (Clone P30-15), anti-NKP44 (Clone 3.43), anti-NKP46 (Clone 
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KIR3DL1(Clone DX9) (all purchased from Biolegend, UK) together with PerCP-conjugated 
mouse anti-human CD8 (Miltenyi Biotech, UK) and PE-conjugated mouse anti-human CD3 
(Biolegend UK).  In addition, separate experiments were carried out using a panel of 
antibodies to NK receptor ligands – these were mouse anti-human MICA/B (Clone 6D4 
Biorad, UK), MICA(Clone 4), ULBP-1 and Nectin 2 (polyclonal antibodies) (Biorbyt USA), 
HLA-ABC (W6/32, Biolegend UK), HLA- BW4 (0.L.6, US Biologicals, USA), HLA-Class I 
(Tu149, Life technologies, UK), and HLA-G (4H84, SantaCruz, USA). 
Since we had also found that 2.5 ng/ml IL-15 gave more expansion of NK cells than 25 ng/ml 
IL-15[25], expression of the receptors and ligands was measured after the 7 day co-culture 
incubations with either PBS, low dose IL-2 (10 units/ml), high dose IL-2 (100 units/ml), IL-
15 (2.5 ng/ml) or IL-15 (2.5 ng/ml) plus IL-2 (10 units/ml). Low dose IL-2 was included in 
order to resemble the microenvironment of prostate cancer where it is known that IL-2 is 
present in very small amounts and is also present in the sera of patients [27]. 
For selected ligands that have been shown to be shed from the tumour cell surface – i.e 
MICA, Nectin2 –ELISAs (Biolegend UK) were performed to measure levels of these ligands 
in the supernatants of PBMC – tumour cell co-cultures. 
 
Inhibition of NKG2D in the PBMC –tumour cell co-cultures    
  
To assess whether blocking of NKG2D could inhibit the expansion seen in the tumour cell-
lymphocyte co-cultures, the 7 day co-cultures were performed with either a blocking 
antibody to NKG2D (Ultra-LEAF™ Purified anti-human CD314 (NKG2D) Antibody [Clone: 











This article is protected by copyright. All rights reserved. 
IgG1, κ Isotype Ctrl Antibody [Clone: MOPC-21] (Biolegend UK Ltd). The antibodies were used 
at 10µg/ml as suggested in previous papers  that showed blocking of NKG2D activity in NK 
cells, and NKG2D mediated tumour cytotoxicity  with this antibody [28, 29]. After 7 days, the 
co-cultures were analysed for any inhibition of expansion that had been mediated by IL-15.  The 
antibody activity was confirmed by analysing NKG2D expression on the NK cells, which was 
completely inhibited (data not shown).  
 
HSP90 and HSP70 ELISAs   
ELISAs were performed for Hsp70 and 90 according to the manufacturer’s instructions 
(Biolegend, UK) in the supernatants of the co-cultures of PNT2, WPMY-1, LNCaP and PC-3 
with lymphocytes to determine whether levels were lower in the non-cancerous, compared to 
the tumour cells.  
 
Results 
IL-15 expands NK, NKT and CD8 T cell populations within prostate cancer –lymphocyte 
co-cultures  
To examine the effect of prostate cells on the expansion of immune effector cells in a 
lymphocyte population cultured with a panel of cytokines previously shown to expand NK 
cells, we cocultured prostate cells (either cancer cells or non-cancerous lines) with 
lymphocytes from normal donors. Figure 1 shows that with all prostate cell line –lymphocyte 
co-cultures tested, IL-15, but not IL-2, IFN-γ, IL-12 or IL-21 gave rise to expansion of NK 




 cells) and 
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increased NK cell numbers over fivefold on average with PC-3 and LNCaP cells (n = 6, 
*p<0.05 by one-way anova and Newman Keuls post-hoc tests), whereasWPMY-1 and PNT2 
cell co-cultures increased NK numbers by an average of 2.1-fold, similar to the expansion 
seen in lymphocytes alone. The expansion of NK cells with PC-3 and LNCaP was 
significantly greater than with lymphocytes alone (n= 6, ** p <0.05 by one-way anova and 
Newman Keuls post-hoc test). Therefore, IL-15 treatment of lymphocytes with both PC-3 and 
LNCaP cancer cell lines, but not the non-cancerous prostate cells, can increase expansion of 
NK cells to a much greater extent than in lymphocytes alone.   NKT cells were expanded by 
an average of threefold and expansion was similar in co-cultures with all prostate cells with 
or without tumour cell contact and occurred to the same extent in lymphocytes cultured alone 
treated with IL-15 (n= 6, ** p <0.05 by one-way anova and Newman Keuls post-hoc test). 
CD8 T cells were increased by up to 1.5-fold in lymphocytes alone, by IL-15, but expansion 
was less when lymphocytes were in contact with PC-3 cells, whereas no expansion was 
observed in PNT2 cells, compared to the control (PBS) group. Using lymphocytes cultured 
without prostate cells, the cytokines IL-2, and IL-12 showed a moderate expansion of NK 
cells, and IFN-γ and IL-12 expanded NKT cells, but again, only IL-15 expanded CD8 T cells. 
Tregs were only increased in lymphocytes alone treated with IL-2. IL-15 inhibited Tregs both 
in lymphocytes alone and in the co-cultures.  
 
Activity of IL-15 in the prostate cancer-lymphocyte co-cultures is not prostate cell-contact 
dependent for NK cell expansion or CD8 expansion 
To examine whether contact of lymphocytes with prostate cancer cells was required for 
enhanced NK cell expansion, we included conditions in the co-culture assay where 
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insert which would inhibit cell-cell contact. Figure 1b shows that in the presence of IL-15, 
there is no significant difference in expansion of NK, NKT or CD8 T cells when the cell lines 
are in contact with the non-adherent lymphocytes, compared to their expansion when there is 
a 0.4 µm transwell membrane (insert).   
 
IL-15 increases the anti-tumour cytotoxic activity of NK, NKT and CD8 T cells in the co-
cultures. 
The cytotoxic activities of the NK, NKT and CD8 T cells were all increased by IL-15 as 
measured by a significant increase in intracellular expression of perforin (Figure 2b) and 
killing of the tumour cells measured with Annexin/PI staining (Figure 2a) (n= 6 experiments, 
* p<0.05 by one-way anova and Newman Keuls). CD107a was increased with IL-15 in NK 
cells but not in CD8 or NKT cells (Figure 2c). The gating strategy to investigate antitumour 
toxicity is shown in Supplementary Figure 1. The spontaneous background killing seen with 
PC3 and LNCaP cells alone is similar to the killing seen in the presence PBMCs with PBS. 
(Supplementary Figure 2) 
To demonstrate that the expansion of NK cells in the human lymphocyte tumour cell 
cocultures was not due to an allogeneic response caused by a mismatch of MHC in the two 
populations, we repeated the NK expansion and tumour cell killing experiments in the murine 
syngeneic model where the TRAMP-C1 tumour cells are derived from C57/BL6 mice, which 
are also used for their splenocytes. In the murine syngeneic prostate tumour cell – splenocyte 
co-cultures (Figure 3), again, IL-15 led to expansion of NK cells in the co-cultures that was 
on average, five-fold greater than splenocytes incubated with IL-15 alone (n= 3 experiments, 
*p<0.05 by one-way anova and Newman Keuls). This effect also occurred with NKT cells, 
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the human co-culture model. Tumour cell killing of TRAMP-C1 cells was again only 
observed with IL-15. 
 
Tumour cell killing in the co-cultures is mediated by NK cells and not CD8 T cells.  
When co-cultures of PC-3 or LNCaP tumour cells were prepared with lymphocytes depleted 
of CD8 T cells, the expansion of NK cells and killing of the tumour cells remained similar to 
that with co-cultures containing non-depleted lymphocytes (Figure 4).  When CD56+ cells 
were depleted, there was no increased killing seen higher than the tumour cell only control, 
therefore the tumour killing in the co-cultures is mediated by NK cells or NKT cells, and not 
CD8 T cells (n= 4 experiments for each condition). The efficacy of CD56+ and CD8 T cell 
removal is shown in dot plots in Supplementary Figure 3. Tumour cell killing in the murine 
syngeneic co-culture model is also mediated by NK cells (Supplementary Figure 4) as the 
killing by MHC class II depleted splenocytes and purified murine NK cells is similar and no 
killing is seen with murine purified CD8 T cells. 
 
IL-15 modulates NKG2D, DNAM-1 and the NK ligands HLA-BW4, ULBP1 and Nectin 2 
in both PC-3 and LNCaP co-cultures. 
We wanted to examine whether the IL-15-mediated increased expansion of NK cells in the 
presence of PC-3 and LNCaP cells was associated with modifications in the expression of 
NK receptors on the NK cells, or NK receptor ligands on the tumour cells. Among the NK 
receptors studied (KIR2DL1, KIR2DL2, KIR3DL1, NKp30, NKp44, NKp46, DNAM-1, and 
NKG2D), only DNAM-1 and NKG2D were significantly upregulated by IL-15 (Figure 5) (by 
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with KIR2DL1, KIR2DL2, KIR3DL1, NKp30, NKp44 and NKp46 are not shown. The 
gating strategy to measure NK receptor expression is shown in supplementary Figure 5. 
Among the NK ligands, HLA-BW4, ULBP1 and Nectin 2 were significantly inhibited in both 
PC-3 and LNCaP cells co-cultured with lymphocytes (Figure 6), however, MICA was 
strongly inhibited in LNCaP cells only. To determine whether IL-15 was inhibiting shed 
MICA, Nectin 2 and ULBP1, we performed ELISAs on the supernatants from the co-
cultures. MICA shedding was decreased significantly in both PC-3 and LNCaP cells (by 50% 
and two-fold respectively- n= 4,  ****p<0.0001 by one-way anova and Newman Keuls post-
hoc test), whereas there was no effect on Nectin 2 secretion (Figure 7), and ULBP1 was not 
detected (data not shown).  
 
Inhibition of NKG2D does not prevent expansion of NK cells in the PC-3 or LNCaP –
lymphocyte co-cultures.  
When we performed blocking experiments on the lymphocyte-tumour cell co-cultures by 
adding a blocking antibody to NKG2D (or the isotype control) (Figure 8), there was no 
significant difference seen in the expansion of the NK cells in the co-cultures.  Therefore 
NKG2D, although increased, does not play a role in the expansion of the NK cells. 
 
Hsp90 and HSp70 are secreted from both cancerous (PC-3) and non-cancerous cells 
(PNT2, WPMY-1)  
Although PC-3 secreted large amounts of HSP90 (>100 ng/ml), as seen by ELISA, there was 
little or no secretion by LNCaP cells and significant secretion by PNT2 cells (>20 ng/ml) 
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whereas PC-3 and LNCaP had low levels of the protein in the supernatant (<15 ng/ml) and 
WPMY-1 had moderate levels (>20 ng/ml).  
 
Discussion 
There is a strong rationale that intratumorally targeted immunotherapeutics will be more 
effective and less toxic than those that are systemically administered [30, 31] and could also 
be used in late stage disease due to the abscopal phenomenon, where for example, IL-2 
injected into melanoma lesions can clear distant metastases [32, 33].  In prostate cancer, 
intratumoural administration is easily possible due to the availability of MRI guided biopsy 
technologies where needles can deliver agents accurately to the lesion, in addition to taking 
biopsies [34]. 
In the present study we sought to determine whether cytokines with known NK and T cell 
activating properties would be able to activate these cells in the presence of prostate cancer 
cells, in order to identify cytokines that could be used intratumourally in prostate cancer 
patients Some previous studies have shown expansion of NK cells with IL-15 using “feeder” 
leukemia cells but none have used prostate cancer cells [35]. Although an in-vitro co-culture 
system cannot compare with a complex in-vivo tumour microenvironment, the knowledge 
that prostate cancer cells exert much of the immunosuppressive effects on immune effector 
cells in this milieu [2] can give us an indication of cytokines that would be functional in this 
environment.  Also, the use of metastatic prostate cancer cell lines PC3 and LNCaP, which 
are highly tumorigenic, enables us to identify cytokines that can work despite this extra 
degree of immunosuppression that is exerted, compared with primary prostate tumour cells.   











This article is protected by copyright. All rights reserved. 
is a potent activator of NK, NKT cells and CD8 T cells. The cytokines IL-2, IL-12, IFNγ, and 
IL-21 can also activate NK cells and CD8 T cells: IL-2, IL-12 and IL-15 induce cytotoxic 
activity of NK cells toward K562 tumour cells to a similar extent [36]. However, in the 
present study only IL-15, among these cytokines, expands NK cells in the presence of 
prostate cancer or non-cancerous cells. The expanded cells are functional as both perforin and 
CD107a expression on NK cells are increased and cytotoxicity toward prostate cancer cells is 
also seen. 
The action of IL-15 on effector cells in the presence of prostate cancer cells is not due to an 
alloreactivity of the effector cells toward the tumour cells as NK and CD8 T cells are also 
expanded within syngeneic co-cultures of murine C57/BL6 lymphocytes and TRAMP-C1 
tumour cells in the presence of IL-15, but not other cytokines (as listed above).  
 
Based on the lack of killing seen with CD56 depleted lymphocytes, and also with purified 
CD8 T cells in mice, the killing of prostate cancer cells in this model is due to NK/NKT cells. 
Therefore, although CD8 T cells are expanded and activated by IL-15, as expected these cells 
are not primed to kill tumour cells in an antigen dependent manner in this model as there are 
minimal numbers of APCs within the non-adherent lymphocytes.  
NK cells are important in the anti-tumour immune response of Prostate Cancer patients: 
Overall survival (OS) and time to castration resistance (TCR) in metastatic prostate cancer 
patients are closely correlated with the efficacy of the NK cells (their ability to kill prostate 
cancer cells and high levels of activating receptors such as NKG2D)  in these patients[37]. 
Furthermore, infiltration of NK cells into the cancerous prostates of men analyzed after 
prostatectomy correlated with a lower risk of progression after androgen deprivation therapy 
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A number of studies have examined adoptive transfer of NK cells for immunotherapy. These 
studies have had varying success depending on the types of tumour or whether NK cells were 
allogeneic or autologous: Studies using allogeneic NK cells have been successful in patients 
with  melanoma, renal cell carcinoma, refractory Hodgkin’s disease and refractory AML 
whereas use of autologous cells has proved less successful[39]. However, these studies have 
so far not used IL-15 as an expanding cytokine, due to its previously poor availability in 
GMP form. The use of IL-15 may be a game changer in these therapies[40].  
   
Based on our finding that IL-15 increases NKG2D in NK cells co-cultured with tumour cells 
compared to lymphocytes cultured alone, and concomitantly decreases  shed MICA, we 
posited that the interaction of NKG2D with its ligands on tumour cells may be at least a 
partial reason for the expansion of the NK cells in the co-cultures. Although the MICA 
binding to NKG2D is contact-based, it is known that some forms of shed ligands can activate 
NKG2D, at least in the mouse, and this may be occurring through as yet unknown ligands in 
the co-cultures where an insert is present [41]. Also, NKG2D is activated directly by IL-15 
and its expression is increased, but further activation may be occurring because of the 
inhibition of MICA shedding.  
When we block NKG2D in our co-cultures with a blocking antibody however, there is little 
or no effect on expansion of the NK cells, suggesting that other molecules from the tumours 
are increasing the expansion of NK cells in the presence of IL-15.  We wanted to study 
whether this was related to the expression of molecules in tumorigenic cells that were not 
expressed in normal cells. One such group of molecules are heat shock proteins, (HSPs), 
molecules first identified as proteins up-regulated with elevated temperature. Recently it was 
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can constitutively secrete these molecules and also express them on the cell surface [20, 42-
44]. We have studied the involvement of HSP90 and HSP70 in the IL-15 mediated expansion 
of NK cells due to previous studies reporting where it has been reported that HSP90 and 
HSP70 are critical for NK cell function[21] [22].  
However, our ELISAs show that whereas HSP90 is secreted at high levels in PC-3 cells, 
there is almost no secretion in LNCaPs and significant expression in WPMYI cells and PNT2 
cells.  
Therefore, other soluble factors must be in play to contribute to the increased NK expansion. 
It is also possible that expansion of NK cells is enhanced due to the greater availability of IL-
15 occurring in the presence of prostate cancer cells: In tissues expressing IL-15R alpha, IL-
15 is retained due to cell endosomes internalizing but not degrading IL-15-IL-15 receptor 
alpha complexes[45], and we have shown that prostate cancer cells express IL-15 alpha 
receptor, although this has no effect on prostate cell proliferation[46].  
In summary, IL-15 can expand NK cells within co-cultures of lymphocytes and tumour cells, 
unlike IL-2, IL-12, IL-21 or IFNγ. This suggests that IL-15 may be a potent 
immunotherapeutic agent when administered intratumourally in prostate cancer. We are 
therefore now patenting a novel localisable form of this agent, and a first-in man trial with 
intratumoural IL-15 is planned imminently.  
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Figure Legends 
Figure 1 : Expansion of immune effector cell populations in the presence or absence of 
prostate cancer cells or normal prostate cells (with or without contact with lymphocytes 
“membrane inserts”) treated with 25 ng/ml of IL-15,IL-2, IL-12, IFN-γ, IL-21 or PBS 
(control). Figure (1a) Gating strategy for NK cells showing the significant increase in 
CD56+CD3- cells in PC3 and LNCaP co-cultures treated with IL-15 compared to 
lymphocytes treated with IL-15 alone. Figure (1b) Quantitated expression of NK, NKT, CD8 
T cells and Treg effector cells in the co-cultures of prostate cells and lymphocytes compared 
to lymphocytes alone. Results are expressed as % of the expression of cells obtained for the 
control (PBS) cultures as the expression of the effector cells differed widely with different 
donors. Culture with tumourigenic cell lines PC-3 and LNCaP increases expansion of NK 
cells by IL-15 to a greater extent (up to 5.1 fold) than lymphocytes cultured with IL-15 alone 
(2.1 fold) (n= 6, ** p<0.05 by one-way anova and Newman Keuls post hoc tests) and occurs 
independently of tumour cell contact i.e. expansion is not significantly different in the 
presence or absence of a membrane insert placed in the well to separate lymphocytes and 
prostate cells. The non-tumorigenic cell lines WPMY-1 and PNT2 cocultured with 
lymphocytes and IL-15 have NK cell expansion to the same extent as in lymphocytes alone 
treated with IL-15.  The cytokines IL-2 and IL-12 give a small expansion of NK cells in 
lymphocytes alone but no expansion occurs in the co-cultures with any cytokine except IL-
15. NKT cell expansion with IL-15 is similar in co-cultures of all prostate cells with or 
without tumour cell contact and occurs to the same extent in lymphocytes cultured alone with 
IL-15 (up to a 4-fold increase). CD8 expansion is seen only with IL-15 in lymphocytes alone 
or in co-cultures (up to a 1.5 fold increase, n= 6,  * p <0.05 by one-way anova and newman 
Keuls post-hoc analysis). There is no significant difference in CD8 expansion when a 
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analysis of Treg expression shows that IL-15 inhibits Tregs either with lymphocytes alone or 
in the co-cultures with prostate cells. Results are the means +SEM from 6 separate 
experiments (n= 6, * p < 0.05, ** p < 0.01 by one-way anova and Newman Keuls post-hoc 
analysis). 
 
Figure 2: IL-15 treatment induces effector cell-mediated killing of PC-3 and LNCaP cells in 
lymphocyte-tumour cell co-cultures (Fig 2a). The killing of PC-3 and LNCaP is increased to 
a mean of 55 and 60% as measured by annexin+ PI+ cell expression, compared with 15-20% 
in the co-cultures incubated with PBS (this is the same background cell death seen in the 
irradiated tumour cells alone after 7 days) (n = 4 * p<0.05 by one-way anova and Newman 
Keuls post hoc test). IL-12 and IL-21 also increased the cell killing in PC-3 cells, but not 
LNCaP. This is concomitant with an increased perforin in the NK, NKT and CD8 T cells in 
IL15 treated co-cultures compared to the PBS control (n= 4, * = p < 0.05 by one-way anova 
and Newman Keuls post hoc test)(Figure 2b). CD107a was also increased by IL-15 in the NK 
cells, but not NKT or CD8 T cells (n= 4, * p < 0.05 by one-way anova and Newman Keuls 
post hoc test) (Figure 2c). 
 
Figure 3: IL-15 increases NK, NKT and CD8 T cell expansion, and tumour cell killing in 
murine C57/BL6 syngeneic splenocyte: TRAMP-C1 co-cultures (Panels A, B, C and D 
respectively). Splenocytes were depleted of MHC class II expressing cells as described in the 
materials and methods. Co-cultures of these splenocytes were then set up at an 8:1 ratio with 
irradiated TRAMP-C1 cells for 9 days in the presence of either PBS or murine IL-2, IL-12, 
IFN-γ, IL-15 or IL-21, all at 25 ng/ml. Cells were harvested and effector cell expression was 
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that NK cells are expanded in IL-15 treated splenocytes alone and in the co-cultures, with NK 
cell expansion being significantly higher (five-fold) in the co-cultures compared to 
splenocytes alone with IL-15 (n= 3, **p <0.05 by one-way anova and Newman Keuls post 
hoc test). NKT and CD8 T cells are also significantly expanded in IL-15 treated co-cultures, 
but not in the splenocytes cultured with IL-15 alone (n= 3, * p <0.05 by one-way anova and 
Newman Keuls post hoc test). The presence of an insert separating splenocytes and tumour 
cells again does not affect expansion of the NK and NKT effector cells. Effector mediated 
cell killing of TRAMP-C1 cells (carried out as described in the materials and methods) also 
occurs only with IL-15 incubation in co-cultures (Fig. 3D).  
 
Figure 4: PC-3 and LNCaP killing in the tumour cell-lymphocyte co-cultures is mediated by 
CD56+ cells and not CD8 T cells. Results are expressed as increases in killing of PC3 or 
LNCaP cells in co-cultures treated with IL-15 (black columns) compared to the control 
killing in co-cultures with the PBS control(grey columns)  in the three preparations 
respectively (n= 3,* p <0.05 by one-way anova and Newman Keuls post hoc test). Depleted 
lymphocytes had levels of CD8 or CD56+ cells that were less than 0.1% of the lymphocyte 
population. The level of the cell killing in the control co-cultures was between 15-20% as 
previously observed. Data was normalized so the control co-cultures with depleted and non-
depleted populations of lymphocytes were set at 100%. 
 
Figure 5. Effects of IL-15 on the expression of NK receptors NKG2D and DNAM-1.  IL-15 
treatment of lymphocytes increases NKG2D expression on NK cells compared to that in 
PBMCs treated with PBS or IL-2 (n = 6,  *p<0.05 by one-way anova and Newman Keuls 
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increased further compared to IL-15 treated lymphocytes alone (n= 6, ** p<0.01 by one-way 
anova and Newman Keuls post-hoc test).  DNAM-1 expression is also increased with IL-15 
to a similar extent in lymphocytes alone or with tumour cell co-cultures (n= 6, * p<0.05 by 
one-way anova and Newman Keuls post-hoc test).  The addition of low dose IL-2 does not 
significantly inhibit the effects of IL-15 on these receptors.  
 
Figure 6: Effects of IL-15 on the expression of NK ligands on PC-3 and LNCaP tumour cells 
in lymphocyte co-cultures or cultured without lymphocytes. IL-15 and IL-15 + low dose IL-2 
inhibits the expression of the NK ligands ULBP-1, HLA-G and HLA-BW4 on both PC-3 and 
LNCaP cell lines co-cultured with lymphocytes. Results are expressed as the percentage of 
expression in PBS control PC-3 or LNCaP co-cultures or tumour cells alone (n= 6, * p<0.05 
by one-way anova and Newman Keuls post-hoc test).  MICA, Nectin 2 and HLA- Class I are 
inhibited by IL-15 and IL-15 + low dose IL-2 only in LNCaP cells co-cultured with 
lymphocytes (n= 6, * p<0.05 by one-way anova and Newman Keuls post-hoc test). 
 
Figure 7: Effects of IL-15 on shedding of the NKG2D ligands MICA and Nectin 2: IL-15 and 
IL-15 plus 10 units/ml IL-2 inhibits shedding of MICA in PC-3 and LNCaP cells but not 
Nectin 2. In PC-3 cell cocultures with lymphocytes, MICA is lowered from a mean of 3000 
pg/ml to 2500 pg/ml with IL-2 (both at 10 units/ml and 100 units/ml) but is lowered to a 
mean of 2000 pg/ml with IL-15 or IL-15 and low dose IL-2 (n= 4 **  p<0.05 with one-way 
anova and Newman Keuls post hoc test, **** p <0.001 with one-way anova and Newman 
Keuls post hoc test). In LNCaP co-cultures, shed MICA is lowered from an average of 400 
pg/ml to an average of 100 pg/ml in both IL-15 and IL-15 + low dose IL-2, (n= 4, *** p 
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Figure 8: Antibodies to NKG2D do not inhibit the increased expansion of NK cells by IL-15 
in the presence of LNCaP (top panel) or PC-3 (bottom panel) cells. LNCaP or PC-3-
lymphocyte cocultures set up for 7 days in the presence of 10 µg/ml blocking NKG2D 
antibody (R and D systems, UK) were harvested and NK cell expansion was measured by 
flow cytometry (BD FACsCalibur™). The expansion of NK cells was increased by IL-15 in 
lymphocytes cultured without tumour cells (n = 6, *p <0.05 by one-way anova and post hoc 
Newman Keuls test) and was greater in IL-15 treated lymphocyte co-cultures with PC-3 or 
LNCaP  than with IL-15 treated lymphocytes only (n=6 **p <0.01 by one-way anova and 
post hoc Newman Keuls test) but NKG2D antibodies did not significantly affect expansion in 
these co-cultures.  
Figure 9:  HSP90 and HSP70 are secreted by both cancerous (PC-3 and LNCaP) and non-
cancerous WPMY-1 and PNT2) cell lines. PC-3 secretion of HSP90 increases with IL-15 in 
lymphocyte co-cultures up to 100 ng/ml but LNCaP and WPMY-1 secretion of HSP90 is 
negligible (<10 ng/ml with any treatment. n= 3 experimental repeats). PNT2 secretion of 
HSP90 is moderate (>20 ng/ml, n= 3 experimental repeats). With HSP70, PNT2 cells secrete 
the largest amounts (>60 ng/ml, n= 3 experimental repeats) with low amounts secreted by 
PC-3, LNCaP, and WPMY-1. Therefore, there is no correlation between HSP90 or HSP70 
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Supplementary Figure 1: Gating strategy and representative dot plots showing tumour cell 
cytotoxicity in lymphocyte: LNCaP cell co-cultures treated with PBS and IL-15 respectively 
as measured by Annexin IV and propidium iodide.  
 
Supplementary Figure 2: Killing of PC3 and LNCaP tumour cells by non-adherent PBMCs. 
The graph shows that the background annexin/PI staining (representing cell death) in the PC3 
and LNCaP cultures alone is similar to the percentage of staining with PC3 or LNCaP cells 
cocultured with non-adherent PBMCs with PBS or IL-2 (15-20%). Killing is increased to 50-
60% in the co-cultures in the presence of IL-15. (n=3, * = p<0.05, by one way anova and post 
hoc Newman Keuls test).  
Supplementary Figure 3: Dot plots showing the lack of CD8 or CD56+ cells in lymphocytes 
depleted of these cells by the Miltenyi cell isolation kits for removal of CD8 or CD56+ cells.  
Supplementary Figure 4: Killing of TRAMP-C1 cells in the MHC-class II depleted 
splenocyte -TRAMP_C1 co-cultures is mediated by NK cells and not CD8 T cells. The 
results are expressed as the percentage of dead TRAMP-C1 cells observed when TRAMP-C1 
cells are co-cultured for 24 hrs with either MHC class II depleted splenocytes, purified NK 
cells or purified CD8 T cells that have been previously cultured for 9 days with TRAMP-C1 
cells. N= 3 *p <0.05 by one way anova and post hoc Newman Keuls tests.  The ratios of cells 
used for the co-cultures were 8:1 (effector: target) for the MHC-Class II depleted splenocytes, 
4:1 for the NK cells and 4:1 for the CD8 T cells. 
Supplementary Figure 5: Gating strategy to measure NK cell receptors in NK cells in the 
lymphocytes alone or lymphocyte: tumour cell co-cultures. The lymphocyte gate is selected 
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(Top left quadrant gate in middle dot plot). This second gate is then used to plot FL1 (which 
measures the NK cell receptors as these are all FITC conjugated antibodies), and FL3 (which 
is the CD8 –PerCP channel in this experiment and should be at background level as NK cells 
are not normally CD8+). Receptor expression is then taken from the bottom right quadrant 
which measures NK cells with the receptor, e.g NKG2D or KIR2DL1. 
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